FinnCap reaffirmed their corporate rating on shares of Allergy Therapeutics (LON:AGY) in a research report released on Wednesday. The brokerage currently has a GBX 47 ($0.65) price target on the stock.

Separately, Numis Securities reissued a buy rating and set a GBX 45 ($0.62) price objective on shares of Allergy Therapeutics in a research report on Wednesday, January 31st.

Shares of Allergy Therapeutics (LON:AGY) opened at GBX 25.62 ($0.35) on Wednesday. Allergy Therapeutics has a 12-month low of GBX 23 ($0.32) and a 12-month high of GBX 39.50 ($0.55).

TRADEMARK VIOLATION WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.